228 related articles for article (PubMed ID: 26433850)
21. Therapeutic Update: Update on Cutaneous and Systemic Therapy for Primary Cutaneous T Cell Lymphoma, Mycosis Fungoides.
Lo Sicco K; Latkowski JA
J Drugs Dermatol; 2015 Dec; 14(12):1381-3. PubMed ID: 26659928
[No Abstract] [Full Text] [Related]
22. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
23. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
[TBL] [Abstract][Full Text] [Related]
24. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
25. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
Huen AO; Kim EJ
Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
[TBL] [Abstract][Full Text] [Related]
26. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
27. Topical treatment of early cutaneous T-cell lymphoma.
Ramsay DL; Meller JA; Zackheim HS
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
[TBL] [Abstract][Full Text] [Related]
28. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.
Durgin JS; Weiner DM; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):587-595. PubMed ID: 33352267
[TBL] [Abstract][Full Text] [Related]
29. In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66. PubMed ID: 25988964
[No Abstract] [Full Text] [Related]
30. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Heald PW; Glusac EJ
J Am Acad Dermatol; 2000 Feb; 42(2 Pt 1):283-5. PubMed ID: 10642687
[TBL] [Abstract][Full Text] [Related]
31. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
32. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol.
French LE; Saurat JH
Lancet; 1995 Aug; 346(8971):376. PubMed ID: 7623546
[No Abstract] [Full Text] [Related]
33. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
34. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
35. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
36. Limited effect of chemotherapy in cutaneous lymphoma.
Vermeer MH; Willemze R
Blood; 2015 Jan; 125(1):4-5. PubMed ID: 25554742
[No Abstract] [Full Text] [Related]
37. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
38. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
39. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
Masuzawa M; Takasu H; Amoh Y
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
